ARS Pharmaceuticals, Inc.
SPRY
$13.77
-$0.87-5.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 114.71% | 20.32% | 15.94% | -17.23% | -56.75% |
| Total Depreciation and Amortization | 8.22% | -17.33% | 1.64% | 1,500.00% | 114.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 204.99% | -35.76% | -40.67% | -56.26% | -67.41% |
| Change in Net Operating Assets | 75.42% | 77.97% | 59.88% | 32.72% | 42.28% |
| Cash from Operations | 122.86% | 26.46% | 20.12% | -17.47% | -47.88% |
| Capital Expenditure | -221.71% | 56.63% | 80.74% | 82.48% | 12.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -21.30% | 119.36% | 37.17% | 114.30% | -- |
| Cash from Investing | -21.70% | 119.14% | 37.42% | 114.19% | -43,709.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -56.28% | -38.85% | -20.80% | 209.05% | 1,110.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 949.41% | -98.35% | -98.20% | -96.97% | -96.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.56% | -189.94% | -210.70% | -189.35% | -192.75% |